ClinicalTrials.gg
RecruitingNCT07855783Updated Oct 7, 2026

Machine-Learning Prediction of Pregnancy Outcomes After Assisted Reproductive Treatments

An observational study in IVF Outcomes, Prediction Models and Infertility Assisted Reproductive Technology, sponsored by BetaPlus Center for Reproductive Medicine. Recruiting at 2 sites in Croatia. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by BetaPlus Center for Reproductive Medicine · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 7, 2026Eligibility revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
2,200
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The goal of this observational study is to develop and validate a machine-learning model to predict pregnancy outcomes in women with a positive pregnancy test following assisted reproductive treatment (ART), with the primary analysis focusing on in vitro fertilization (IVF) and frozen embryo transfer (FET). The study will also include an exploratory analysis of pregnancies following intrauterine insemination (IUI). The main questions addressed by the study are:

Can early blood levels of beta-human chorionic gonadotropin (beta-hCG) predict the likelihood of live birth in an IVF or FET cycle? Can early beta-hCG levels help identify pregnancies at increased risk of biochemical pregnancy or early pregnancy loss?

Participants will have clinical and treatment information, including beta-hCG measurements and pregnancy outcomes, collected from medical records or during prospective follow-up. No changes to participants' medical treatment will be made as part of the study.

Read the detailed description

Infertility affects more than 15% of the global population, and ART are increasingly used to achieve pregnancy. The field continues to evolve rapidly with ongoing technological and clinical advances. Although these advances have improved ART, success rates continue to vary, contributing to significant psychological distress among patients due to uncertainty regarding outcomes.

The most intense stress typically occurs after the procedure, especially following a positive pregnancy test and before ultrasound confirmation. This period, which lasts at least 3-4 weeks, is characterized by considerable uncertainty, as neither patients nor healthcare providers have reliable tools to determine pregnancy viability, assess early development, or accurately predict pregnancy progression. An individualized assessment of the probability of live birth after a positive pregnancy test could provide clinically meaningful information during this period and potentially improve counseling and management of patient expectations.

Serum beta-hCG is one of the earliest measurable biomarkers following embryo implantation and has long been recognized as an important prognostic marker of early pregnancy outcome. Both the absolute concentration of beta-HCG and its subsequent rate of increase have been associated with pregnancy viability and live birth following embryo transfer.

Investigators plan to use a machine-learning system to collect and analyze retrospective clinical data. Beta-HCG values from this dataset were collected at very early stages of pregnancy (around aspiration days +14 and 16, and post-FET days 9 and 11).

Patients were advised to have blood drawn for beta-HCG measurement 14 days after oocyte aspiration or insemination, followed by a second measurement two days later. For FET, measurements were taken 9 days after blastocyst transfer (or the corresponding day for cleavage-stage embryos) and two days afterward. Due to scheduling constraints, such as weekends, actual measurements may have occurred one day earlier or later, or several days apart. The dataset included the exact dates of each blood draw, allowing precise calculation of the interval between measurements for analysis.

ART outcomes were primarily collected through direct patient reporting of events, including adverse pregnancy outcomes or live birth; for patients who did not report the outcomes, clinic staff conducted follow-up calls to ensure complete follow-up.

This study is an observational retrospective-prospective cohort study for development and validation of an AI (artificial intelligence) - based prognostic model predicting live birth after ART.

The retrospective phase will use existing clinical data from patients who underwent ART procedures at the BetaPlus Center between January 2017 and 31.12.2025.

The prospective phase will include consecutive patients undergoing ART after model development in both BetaPlus Center and Clinical University Hospital in Rijeka. These patients will be followed to assess pregnancy outcomes, enabling external validation of the model.

The study is observational in nature. No interventions, treatment modifications, or randomization will be performed as part of this research. Clinical management will follow standard operating procedures (SOP) independent of model predictions.

02

Conditions studied

  • IVF Outcomes
  • Prediction Models
  • Infertility Assisted Reproductive Technology
  • Live Birth

Browse trials for

Keywords

  • Prediction model
  • Machine learning
  • Biochemical pregnancy
  • Early pregnancy loss
  • Pregnancy outcome
  • Beta-hCG
  • Assisted reproductive technology
03

In context

Abortion, Spontaneous

221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.

This study's planned enrollment of 2,200 is above the median of 201 across 98 observational studies indexed under Abortion, Spontaneous.

Browse Abortion, Spontaneous studies →

Lead sponsor

This is the only study on the registry with BetaPlus Center for Reproductive Medicine as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be women undergoing ART at the BetaPlus Center and, during the prospective validation phase, at the Clinical University Hospital in Rijeka, Croatia. The study population will include patients undergoing IVF/ICSI, FET, or IUI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who underwent ART procedures (IUI, IVF/ICSI, or FET) using homologous oocytes.
  • Availability of at least one positive early serum beta-HCG measurement after aspiration, FET, or insemination (beta-HCG >10 mIU/mL).
  • Availability of the pregnancy outcome.
  • Availability of relevant patient characteristics and clinical variables required for predictive modeling.
  • For embryo-transfer cycles, availability of information on embryo developmental stage and number of embryos transferred where applicable.
  • For the prospective validation cohort, written .

Exclusion criteria

Exclusion Criteria

  • Missing beta-HCG measurements critical for model input.
  • Missing key demographic or clinical variables required for predictive modeling.
  • Missing ART treatment protocol where required for the model.
  • Missing pregnancy outcomes.
  • Multiple pregnancy, hydatidiform mole, heterotopic pregnancy, and ectopic pregnancy will be excluded from the primary live-birth analysis but will be described separately and, where sample size permits, evaluated as secondary adverse pregnancy outcomes.
  • Non-consent for prospective participation in validation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
2,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • ART pregnancies with positive beta-hCG

    Patients with a positive serum beta-hCG measurement following ART, including IVF, FET, and IUI. Participants will be followed to assess pregnancy outcomes, including live birth, biochemical pregnancy, and early pregnancy loss.

    Other: Machine-Learning Model for Prediction of Pregnancy Outcomes

Interventions

  • OtherMachine-Learning Model for Prediction of Pregnancy Outcomes

    A machine-learning prognostic model using early serum beta-hCG measurements and patient, embryo, and treatment characteristics to predict live birth and early adverse pregnancy outcomes following assisted reproductive treatment.

06

What researchers measure

Primary outcomes

  1. Live birth following ART

    Delivery of a live infant at ≥24 weeks of gestation.

    Time frame: From positive pregnancy test until delivery.

Secondary outcomes

  1. Biochemical pregnancy following ART

    A pregnancy characterized by a positive serum beta-hCG test followed by bleeding or pregnancy loss without ultrasound confirmation of a clinical pregnancy.

    Time frame: From the first positive serum beta-hCG measurement until biochemical pregnancy resolution.

  2. Early Pregnancy Loss following ART

    Pregnancy loss occurring before 12 weeks of gestation, excluding biochemical pregnancy, ectopic pregnancy, heterotopic pregnancy, and hydatidiform mole.

    Time frame: From clinical pregnancy confirmation until 12 weeks of gestation.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Clarke EA, Jones C, Reckhow J, Flannagan K, Shaari D, Baird M, Lee JA, Sekhon L, Copperman AB, Romanski PA. Prognostic utility of serum beta human chorionic gonadotropin level following single euploid embryo transfer for live birth. Fertil Steril. 2026 Aug;126(2):371-378. doi: 10.1016/j.fertnstert.2026.04.025. Epub 2026 May 4. PubMed 42092529 ↗
  • Papageorgiou TC, Leondires MP, Miller BT, Chang AS, Armstrong AB, Scott LA, Segars JH. Human chorionic gonadotropin levels after blastocyst transfer are highly predictive of pregnancy outcome. Fertil Steril. 2001 Nov;76(5):981-7. doi: 10.1016/s0015-0282(01)02840-0. PubMed 11704121 ↗
  • Mourad A, Antaki R, Rowen M, Levesque E, Lapensee L. The POPI-Plus tool: prediction model of outcome of pregnancy in in vitro fertilization from a large retrospective cohort. Fertil Steril. 2024 Mar;121(3):489-496. doi: 10.1016/j.fertnstert.2023.11.035. Epub 2023 Dec 1. PubMed 38043845 ↗
  • Kidera N, Ishikawa T, Kawamura T, Miyasaka N. Serum human chorionic gonadotropin can predict live birth 7 days after frozen-thawed blastocyst transfer. F S Rep. 2025 Oct 23;6(4):455-461. doi: 10.1016/j.xfre.2025.10.002. eCollection 2025 Dec. PubMed 41473560 ↗
  • Kalafat E, Ata B, Del Gallego R, Freedman A, Hoyos LR, Elkhatib I, Miller KA, Fatemi H, Lawrenz B. Predicting live birth following single euploid frozen-embryo transfer via beta-hCG dynamics: iHOPE prognostic model with external validation. Ultrasound Obstet Gynecol. 2026 Jun;67(6):824-835. doi: 10.1002/uog.70238. Epub 2026 May 24. PubMed 42177810 ↗
  • Schmidt LL, Asch RH, Frederick JL, Rojas FJ, Stone SC, Balmaceda JP. The predictive value of a single beta human chorionic gonadotropin in pregnancies achieved by assisted reproductive technology. Fertil Steril. 1994 Aug;62(2):333-8. doi: 10.1016/s0015-0282(16)56887-3. PubMed 8034081 ↗
  • Hughes LM, Schuler A, Sharmuk M, Schauer JM, Pavone ME, Bernardi LA. Early beta-hCG levels predict live birth after single embryo transfer. J Assist Reprod Genet. 2022 Oct;39(10):2355-2364. doi: 10.1007/s10815-022-02606-w. Epub 2022 Sep 8. PubMed 36074224 ↗
  • Trautner PS, Oppelt P, Resch S, Enzelsberger SH, Ebner T, Shebl OJ. Single day 14 serum hCG values allow prediction of viable pregnancy and are significantly higher in frozen as compared to fresh single blastocyst transfer. J Assist Reprod Genet. 2024 Aug;41(8):2193-2200. doi: 10.1007/s10815-024-03164-z. Epub 2024 Jun 13. PubMed 38867095 ↗
  • Al Mamari N, Al Zawawi N, Khayat S, Badeghiesh A, Son WY, Dahan MH. Revisiting serum beta-hCG cut-off levels and pregnancy outcomes using single embryo transfer. J Assist Reprod Genet. 2019 Nov;36(11):2307-2313. doi: 10.1007/s10815-019-01583-x. Epub 2019 Oct 12. PubMed 31605261 ↗
  • Sarret Y, Reano A, Nicolas JF, Su H, Thivolet J. Bullous pemphigoid and cicatricial pemphigoid: immunoblotting detection of involved autoantigens. Autoimmunity. 1989;2(2):145-53. doi: 10.3109/08916938909019951. PubMed 2491598 ↗
  • Hobeika E, Singh S, Malik S, Knochenhauer ES, Traub ML. Initial maternal serum human chorionic gonadotropin levels in pregnancies achieved after assisted reproductive technology are higher after preimplantation genetic screening and after frozen embryo transfer: a retrospective cohort. J Assist Reprod Genet. 2017 Oct;34(10):1333-1340. doi: 10.1007/s10815-017-0987-2. Epub 2017 Jun 21. PubMed 28639180 ↗
  • Kathiresan AS, Cruz-Almeida Y, Barrionuevo MJ, Maxson WS, Hoffman DI, Weitzman VN, Christie DR, Manko GF, Ory SJ. Prognostic value of beta-human chorionic gonadotropin is dependent on day of embryo transfer during in vitro fertilization. Fertil Steril. 2011 Dec;96(6):1362-6. doi: 10.1016/j.fertnstert.2011.09.042. Epub 2011 Nov 1. PubMed 22047663 ↗
  • Oron G, Shavit T, Esh-Broder E, Weon-Young S, Tulandi T, Holzer H. Predictive value of serum HCG concentrations in pregnancies achieved after single fresh or vitrified-warmed blastocyst transfer. Reprod Biomed Online. 2017 Sep;35(3):272-278. doi: 10.1016/j.rbmo.2017.05.011. Epub 2017 May 30. PubMed 28625759 ↗
  • Oron G, Esh-Broder E, Son WY, Holzer H, Tulandi T. Predictive value of maternal serum human chorionic gonadotropin levels in pregnancies achieved by in vitro fertilization with single cleavage and single blastocyst embryo transfers. Fertil Steril. 2015 Jun;103(6):1526-31.e1-2. doi: 10.1016/j.fertnstert.2015.02.028. Epub 2015 Apr 22. PubMed 25910571 ↗
  • Ozer G. Initial beta-hCG levels and 2-day-later increase rates effectively predict pregnancy outcomes in single blastocyst transfer in frozen-thawed or fresh cycles: A retrospective cohort study. Medicine (Baltimore). 2023 Oct 20;102(42):e35605. doi: 10.1097/MD.0000000000035605. PubMed 37861533 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results of this study will be made available upon reasonable request. The shared dataset will include the clinical and treatment variables necessary to reproduce or further investigate the study findings, including relevant beta-hCG measurements, timing of measurements, ART treatment characteristics, and pregnancy outcomes. Data will not include names, contact information, medical record numbers, or other directly identifying information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication and for 5 years thereafter

Access criteria: Data will be available to qualified researchers, subject to applicable ethical, legal, and institutional requirements

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 43 observational studies under Abortion, Spontaneous, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 91. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Sep 30, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Revised
Oct 7, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 7, 2026
    Eligibility Revised
    + 3 other changes: verification date, description and arm descriptions
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855783
Lead sponsor
BetaPlus Center for Reproductive Medicine
Collaborators
Clinical Hospital Center Rijeka
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Romana Dmitrovic
Contact
romana@betaplus.hr
+385981983563
Romana Dmitrovic
principal investigator · BetaPlus Center for Reproductive Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion